InSite to become indirect wholly owned subsidiary of Sun Pharma on merger
Sun Pharmaceutical Industries announced the successful completion of the cash tender offer by Thea Acquisition Corp. (Thea), an indirect wholly owned subsidiary of Sun Pharma, for all outstanding shares of common stock of InSite Vision Incorporated (OTCBB: INSV, InSite),on 27 October 2015.After the Merger, InSite would be an indirect wholly owned subsidiary of Sun Pharma and InSite will no longer have reporting obligations under the Securities Exchange Act of 1934, as amended.
Powered by Capital Market - Live News
